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Background & Objectives: MSCs can interact with cells of both the innate and adaptive 
immune systems which leads to the modulation of several effector mechanisms based on 
ability to moderate T-cell proliferation and function. Other reports mainly focused on the role 
of TLRs in stem cell proliferation and their potential role in disrupting the differentiation 
capabilities of the stem cells. In the present study invested the coestimolatory effect of 
peptidoglycan-lipopolysacarid TLR2,4 agonist on apoptosis induction in activated T cells by 
mouse mesanchymal stem cell (MSCs).  
Methods: MSCs were isolated from bone-marrow of mice and treated with peptidoglycan-
LPS (10ng/ml) as TLR2, 4-agonist for different times (1h and 12h). Treated cells were co-
cultured with PHA-activated splenic mononuclear cells (MNCs) for 72h at 37 °C in a 
humidified  5% CO2 . Apoptosis in activated T cells were then measured using Acridin-
Orange/PI staining in flow cytometry. 
Results: We found  that High  term exposure (12h) of MSCs to TLR2,4 agonist 
(peptidoglycan-LPS) con significantly increase of apoptosis in activated T cells in 
comparison  to control group. 
Conclusion:  Our findings suggested that different exposure terms of MSCs to TLR2/4 
agonist, differently affected apoptotic activity of MSCs against activated T cells, so, we 
concluded that TLR2/4 agonist treated MSCs could utilize for moderating the inflammatory 
reactions in autoimmune disorders. 
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